adamantane has been researched along with imatinib mesylate in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chandra, J; Griffin, JD; Hallgren, CG; Kaufmann, SH; Kottke, TJ; Litzow, MR; Mow, BM; Narayanan, VL; Sausville, EA; Svingen, PA; Tefferi, A; Weisberg, E | 1 |
| Avramis, IA; Avramis, VI; Laug, WE; Sausville, EA | 1 |
| Beran, M; Bhalla, K; Chandra, J; Donato, N; Estrov, Z; Flatten, K; Gorre, M; Karp, J; Kaufmann, SH; Loegering, D; Sausville, E; Sawyers, C; Talpaz, M; Tracy, J; Verstovsek, S | 1 |
| Dasmahapatra, G; Dent, P; Grant, S; Nguyen, TK | 1 |
| Basic, I; Chandra, J; Giles, F; Golemovic, M; Kantarjian, H; Manshouri, T; Orsolic, N; Quintás-Cardama, A; Scappini, B; Verstovsek, S | 1 |
| Barnes, DJ; De, S; Melo, JV; Moravcsik, E; van Hensbergen, P | 1 |
| Anderson, KC; Barilà, D; Chauhan, D; DePinho, RA; Hideshima, T; Podar, K; Raab, MS; Raje, N; Sattler, M; Tai, YT; Tonon, G; Yasui, H; Zhang, J | 1 |
| Griesser, H; Richert, C; Schwenger, A | 1 |
| Berger, D; Bernthaler, T; Eisenwort, G; Entner, M; Hadzijusufovic, E; Herrmann, H; Hoermann, G; Rülicke, T; Sadovnik, I; Stefanzl, G; Valent, P; Willmann, M | 1 |
9 other study(ies) available for adamantane and imatinib mesylate
| Article | Year |
|---|---|
Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.
Topics: Adamantane; Apoptosis; Benzamides; Caspase 9; Caspases; Drug Synergism; Enzyme Induction; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Hydroquinones; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Protein Biosynthesis; Protein Processing, Post-Translational; Proteins; Pyrimidines; Recombinant Fusion Proteins; Serpins; Transfection; Tumor Cells, Cultured; Tumor Stem Cell Assay; Viral Proteins; X-Linked Inhibitor of Apoptosis Protein | 2002 |
Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Topics: Adamantane; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Humans; Hydroquinones; Imatinib Mesylate; Leukemia-Lymphoma, Adult T-Cell; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Vascular Endothelial Growth Factor A; Vidarabine Phosphate | 2003 |
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.
Topics: Adamantane; Apoptosis; Benzamides; Cell Line, Tumor; Clone Cells; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Hydroquinones; Imatinib Mesylate; Leukemia; Mutation; Oxidative Stress; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Reactive Oxygen Species | 2006 |
Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl.
Topics: Adamantane; Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Hydroquinones; Imatinib Mesylate; Kinetics; Mutation; Oxidative Stress; Piperazines; Point Mutation; Pyrazines; Pyrimidines; Reactive Oxygen Species | 2006 |
Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells.
Topics: Adamantane; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Cells, Cultured; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Humans; Hydroquinones; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Phosphorylation; Piperazines; Pyrimidines; Tyrosine | 2006 |
Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines.
Topics: Adamantane; Animals; Antineoplastic Agents; Benzamides; Benzoquinones; Cell Line, Transformed; Cell Line, Tumor; Clone Cells; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genes, abl; HSP90 Heat-Shock Proteins; Humans; Hydrogen Peroxide; Hydroquinones; Imatinib Mesylate; Lactams, Macrocyclic; Mice; Mutant Proteins; Mutation, Missense; Oxidative Stress; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcr; Pyrimidines; Reactive Oxygen Species; Recombinant Fusion Proteins; Signal Transduction; STAT5 Transcription Factor; Substrate Specificity; Transfection | 2007 |
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.
Topics: Adamantane; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Caspase Inhibitors; Caspases; Cell Growth Processes; Dexamethasone; Humans; Hydroquinones; Imatinib Mesylate; Leukemia, Erythroblastic, Acute; Melphalan; Multiple Myeloma; Piperazines; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-jun; Pyrazines; Pyrimidines; Transfection; Up-Regulation | 2007 |
Encapsulating Active Pharmaceutical Ingredients in Self-Assembling Adamantanes with Short DNA Zippers.
Topics: Adamantane; Cyclosporine; DNA; Doxorubicin; Drug Carriers; Drug Compounding; Drug Liberation; Imatinib Mesylate | 2017 |
Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph
Topics: Adamantane; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Coculture Techniques; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Fibroblasts; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neoplasm Proteins; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Pyrrolidines; Tumor Cells, Cultured; Vildagliptin; Xenograft Model Antitumor Assays | 2018 |